Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-01-04
2009-12-15
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S211100
Reexamination Certificate
active
07632508
ABSTRACT:
Chimeric human-bovine parainfluenza viruses (PIVs) are infectious and attenuated in humans and other mammals and useful individually or in combination in vaccine formulations for eliciting an immune response to PIV or other pathogens. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric PIV genome or antigenome which includes a partial or complete human or bovine PIV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different PIV. Chimeric human-bovine PIV of the invention include a partial or complete “background” PIV genome or antigenome derived from or patterned after a human or bovine PIV virus combined with one or more heterologous gene(s) or genome segment(s) of a different pathogen, including different PIV virus to form the human-bovine chimeric PIV genome or antigenome.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis
patent: 4683202 (1987-07-01), Mullis
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6264957 (2001-07-01), Collins
patent: 6764685 (2004-07-01), Haller et al.
patent: 7192593 (2007-03-01), Murphy et al.
patent: 7201907 (2007-04-01), Schmidt et al.
patent: 7250171 (2007-07-01), Tao et al.
patent: 2003/0082209 (2003-05-01), Skiadopoulos et al.
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 92/01471 (1992-02-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 93/21310 (1993-10-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/20468 (1997-06-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/43668 (1998-10-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 99/24564 (1999-05-01), None
patent: WO 00/61611 (2000-10-01), None
patent: WO 00/61737 (2000-10-01), None
patent: WO 01/04271 (2001-01-01), None
patent: WO 01/04321 (2001-01-01), None
patent: WO 01/04335 (2001-01-01), None
Bailly et al., “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) In Which the Nucleocapsid N Protein Has Been Replaced”, Journal Virology, vol. 74, No. 7, 3188-3195 (2000).
Baron et al., “Rescue of Rinderpest Virus From Cloned Cdna”, Journal Virology, vol. 71, No. 2, 1265-1271 (1997).
Bellini et al., “Measles Virus P Gene Codes for Two Proteins”, Journal Virology, vol. 53, No. 3, 908-919 (1985).
Belshe et al., “Cold Adaptation of Parainfluenza Virus Type 3”, Journal Medical Virology, vol. 10(4), 235-242 (1982).
Belshe et al., “Comparison of Enzyme-Linked Immunosorbent Assay and Neutralization Techniques for Measurement of Antibody”, Infect And Immun. vol. 37, 160-165 (1982).
Blumberg et al., “Measles Virus L Protein Evidences Elements of Ancestral RNA Polymerase,” Virology, 164:487-497, 1988.
Buchholz et al., “Chimeric Bovine Respiratory Syncytial Virus With Glycoprotein Gene Substitutions,” Journal Virology, vol. 74, No. 3, 1187-1199 (2000).
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA,” Journal Virology, vol. 73, No. 1, 251-259 (1999).
Bukreyev et al., “Recombinant Respiratory Syncytial virus from which the Entire SH Gene has been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,” J. Virol. 71:8973-8982, 1977.
Bukreyev et al., “Interferon Gamma Expressed By A Recombinant Respiratory Syncytial Virus Attenuates Virus Replication In Mice,” Proc. Natl. Acad. Sci. USA, vol. 96, 2367-2372 (1999).
Bukreyev et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing An Additional, Foreign Gene,” Journal Virology, vol. 70, No. 10, 6634-6641 (1996).
Cadd et al., “The Sendai Paramyxiovirus Accessory C Proteins Inhibit Viral Genome Amplification in Promoter-Specific Fashion,” J. Virol 70: 5067-74, 1996.
Cahour et al., “Growth-Restricted Dengue Virus Mutants Containing Deletions in the 5 Noncoding Region of the RNA Genome,” Virology, vol. 207, 68-76 (1995).
Cattaneo et al., “Measles Virus Editing Provides Additional Cytosine-Rich Protein,” Cell, vol. 56, 759-764, (1989).
Cheng et al., “Effective Amplification of Long Targets From Cloned Inserts,” Proc. Natl. Acad. Sci. USA, vol. 91, 5695-5699 (1994).
Clarke et al., “Rescue of Mumps Virus From cDNA,” J Virology, vol. 74, No. 10, 4831-4838 (2000).
Clements et al., “Comparison of Virologic—Immunologic Resp. of Volunteers To Live Avian-Human Influenza A H3N2 Reassortant,” Journal Clinical Microbiology, vol. 27, No. 1, 219-222 (1989).
Clements et al., “Evaluation of Bovine Cold-Adapted Human, and Wild Type Human Parainfluenza Type 3 Viruses in Adult Volunteers,” J. Clinical Microbiology, vol. 29, 1175-1182 (1991).
Clements et al., “Use of Single-Gene Reassortant Viruses to Study Role of Anain Influenza A Virus,” Journal Clinical Microbiology, vol. 30, No. 3, 655-662 (1992).
Clements-Mann et al., “Safety and Immunogenicity of Live Attenuated Human-Bovine (UK) Reassortant Rotavirus Vaccines VP7 Specificity,” Vaccine vol. 17, 2715-2725 (1999).
Collins et al., “Parainfluenza Viruses,” Fields Virology 3rd ed., Lippincott-Raven Publishers, Philadelphia 1205-1241, (1996).
Collins et al., “Rescue of a 7502-Nucleotide (49.3% of Full-Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA,” Virology 195:252-256, 1993.
Collins et al., “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene,” Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991.
Collins et al., “Production of Infectious Human Respiratory Syncytial Virus From Cloned cDNA,” Pro. Natl. Acad. Sci., vol. 92, 11563-11567 (1995).
Connors et al., “A Cold-Passaged Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes,” Virology 208:478-484, 1995.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,” J. Virol. 68: 713-719, 1994.
Conzelmann et al., “Genetic Manipulation of Non-Segmented Negative-Strand RNA Viruses,” Journal General Virology, vol. 77, 381-389 (1996).
Cook et al., “Antigenic Relationships Among the “Newer” Myxoviruses (Parainfluenza),” Amer. Jour. Hyq. 69:250, 1959.
Cook et al., “In Vivo Antigenic Studies of Parainfluenza Viruses,” American Journal of Hygiene, vol. 77, 150-159 (1962).
Corsoro and Pearson, “Enhancing the Efficiency of DNA Mediated Gene Transfer In Mammalian Cells,” Somatic Cell Genetics, vol. 7, No. 5, 603-616 (1981).
Crookshanks et al., “Evaluation of Cold-Adapted And Temperature-Sensitive Mutants Of Parainfluenza Virus Type 3,” Journal Medical Virology, vol. 13, 243-249 (1984).
Crowe et al., “A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type Challenge in Seronegative Chimpanzees,” Vaccine 12:783-790, 1994.
Crowe et al., “Acquisition of thetsPhenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene,” Virus Genes 13: 269-273, 1996.
Crowe et al., “Cold-Passaged, Temperature-Sensitive Mutants of Human Respiratory Syncytial Virus (RSV),” Vaccine, vol. 13, No. 9, 847-855 (1995).
Curran et al., “The Sendai Virus Nonstructural C
Bailly Jane E.
Collins Peter L.
Durbin Anna P.
Murphy Brian R.
Schmidt Alexander C.
Chen Stacy B
The United States of America
Woodcock & Washburn LLP
LandOfFree
Attenuated human-bovine chimeric parainfluenza virus (PIV)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated human-bovine chimeric parainfluenza virus (PIV)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated human-bovine chimeric parainfluenza virus (PIV)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4126433